Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

subcortical band heterotopia (HeCo) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

subcortical band heterotopia

MONDO:0020491

Also known as:HeCoband heterotopiadouble cortex syndrome

Overview

A developmental brain abnormality characterized by atypical migration of neurons during cortical development.

Patient Orgs1 organizations · PVNH Support & Awareness

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

No HPO annotations are available for this condition.

GeneReviews

Clinical Guidance

DCX pathogenic variants cause an X-linked neuronal migration disorder neuroradiologically comprising an anterior predominant "agyria-pachygyria-band" spectrum of cortical malformations. This includes lissencephaly, referring to a "smooth brain" with a thick cortex and absent (agyria) and/or abnormally wide gyri (pachygyria) in hemizygous males with or without subcortical band heterotopia (SBH). Heterozygous females or rare males with mosaic or "mild" pathogenic variants present with diffuse thick or thin or anterior-predominant SBH, which may be accompanied by frontoparietal pachygyria . To date, more than 300 individuals have been identified with a pathogenic variant in DCX . The following description of the phenotypic features associated with this condition is based on these reports. Table 2. Select Features of DCX-Related Disorders

Diagnosis

Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.

GeneReviews

Diagnostic Criteria

For the purposes of this GeneReview, the terms "male" and "female" are narrowly defined as the individual's biological sex at birth as it determines clinical care . DCX-related disorders are X-linked disorders involving abnormal neuronal migration observed by brain imaging; they include the following:

Classic thick lissencephaly, primarily in males
Subcortical band heterotopia (SBH), primarily in females

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for subcortical band heterotopia. The disease remains an area of unmet medical need.

GeneReviews

Management Guidelines

No clinical practice guidelines for DCX-related disorders have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder. Note: The clinical spectrum observed in individuals with DCX pathogenic variants is extremely broad, from rare, very severely affected males with limited life expectancy to healthy females with a heterozygous or mosaic pathogenic DCX variant who may never develop any clinical features of a DCX-related disorder. Therefore, the information provided in the management section aims to address any clinical issues that may arise, and hence the more severely affected individuals within this clinical spectrum.

Prognosis

Based on GeneReviews surveillance recommendations, HPO phenotype frequency and severity annotations, and published prevalence estimates from Orphanet and OMIM.

GeneReviews

Surveillance Guidelines

To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 6. DCX-Related Disorders: Recommended Surveillance

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for subcortical band heterotopia.

24 publications have been identified in PubMed for subcortical band heterotopia. Research spans Case Report / Case Series (38%), Basic Science / Preclinical (33%), and Review / Meta-Analysis (13%).

Research Type	Count	% of Total
Patient case studies	9	38%

Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 5:04 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Patient Advocacy Groups

View all PAGs →

PVNH Support & Awareness

USWebsite ↗

Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.

Are you a patient organization not listed here? Claim this page to be listed and embed this content on your site — free.

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:99796

GARD

Genetic and Rare Diseases Info Center

GARD:1904

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→How can I connect with PVNH Support & Awareness and other patient organizations for support?

← Back to All Diseases

Feature1	Males2(n=76)	Heterozygous Females3
Ascertained Through Familial Testing4(n=92)	Ascertained Through Diagnostic Workup of Clinical Features5(n=62) Asymptomatic	0%
Abnormal brain imaging (i.e., cortical malformations incl classic lissencephaly)	100%	85%
Neonatal normal	33/33	—
Moderate-to-severe motor impairment	18/33	—
Non-ambulatory	13/33	—
Walking w/support	5/33	—
Walking independently w/o support	15/33	—
Significant speech language impairment	15/33	—
Moderate-to-severe intellectual disability	100%	—
100% Moderate-to-severe behavioral disturbances (incl autistic features, sleep disorder, /or agitation)	10/33	—
60% Truncal hypotonia or spasticity	7/11	—
29% Postnatal microcephaly (OFC 2 SDs below the mean)	30%	—
16% Seizures	83%	—
85% Intractable seizures	49%	78% NA = not applicable; OFC = orbitofrontal cortex; SD = standard deviation 1. , Median age at examination was 7.5 years for 33 individuals reported by Leger et al 2008 (range: 1.5-37 years); age range for 43 individuals reported by was 0.8-37 years.

GeneReviews

Differential Diagnosis

Genes of interest in the differential diagnosis of DCX-related disorders are listed in . Table 3. Genes of Interest in the Differential Diagnosis of DCX-Related Disorders

Gene	Lissencephaly Gradient1	Other Features/ Comment
Diffuse lissencephaly	Posterior-predominant gradient (pa)2	Anterior-predominant gradient (ap)
CDK5	+	Agyria, agenesis of corpus callosum, severe cerebellar pontine hypoplasia, dilated subarachnoid spaces; Dysmorphic facial features, lymphedema, arthrogryposis multiplex; Early lethality4 CRADD
+	+	Other brain malformations typically seen include polymicrogyria, nodular heterotopia, thin corpus callosum, cerebellar basal ganglia abnormalities; Axonal neuropathy seen in some persons KIF2A
+	+	Severe IUGR; Arthrogryposis; Microcephaly6
NDE1	+	Microcephaly; Simplified cortical gyral pattern; Thin or absent corpus callosum; Microhydranencephaly can be seen PAFAH1B1
RNU4ATAC	+	Assoc w/several phenotypes incl microcephalic osteodysplastic primordial dwarfism type I/III, Roifman syndrome, Lowry-Wood syndrome; Brain imaging abnormalities include pachygyria, heterotopia, agenesis of corpus callosum, cerebellar vermis hypoplasia
TUBA1A	+	+

Source: GeneReviews — "DCX-Related Disorders"

Kisho

subcortical band heterotopia

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Treatment

Management Guidelines

Prognosis

Surveillance Guidelines

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Neuroimaging Findings

Differential Diagnosis

Evaluations Following Initial Diagnosis

Neurologic

Constitutional

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Recent Publications

subcortical band heterotopia

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Treatment

Management Guidelines

Prognosis

Surveillance Guidelines

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

External Resources

Orphanet

GARD

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Neuroimaging Findings

Differential Diagnosis

Evaluations Following Initial Diagnosis

Neurologic

Constitutional

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Recent Publications